IQVIA Holdings Inc. reported second-quarter 2026 financial results, announcing revenue of $4,368 million, an 8.7% year-over-year increase. GAAP diluted earnings per share were $1.53, while adjusted diluted EPS rose 12.1% to $3.15. The company generated $994 million in adjusted EBITDA and $558 million in operating cash flow. R&D Solutions net new bookings reached a record $3.15 billion, up 19% year-over-year. IQVIA raised its full-year 2026 guidance, projecting revenue between $17.275 billion and $17.475 billion, adjusted EBITDA between $4.0 billion and $4.05 billion, and adjusted diluted EPS between $12.80 and $13.00. The company operates in the clinical research services, commercial insights, and healthcare intelligence industry.
